Clinical Trial Update: Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update reporting results for adding durvalumab or cetuximab to radiation therapy in locoregionally advanced head and neck cancer patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (Erbitux) (Cetuximab)
• Durvalumab (Imfinzi) (durvalumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-10-25